Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • PD 0332991 (Palbociclib) HCl: Selective CDK4/6 Inhibitor ...

    2026-01-03

    PD 0332991 (Palbociclib) HCl: Selective CDK4/6 Inhibitor for G1 Phase Arrest

    Executive Summary: PD 0332991 (Palbociclib) HCl is a selective, orally bioavailable cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor with sub-20 nM IC50 values for both targets (APExBIO, product page). It arrests cell cycle progression at the G1 phase by blocking Rb protein phosphorylation. The compound demonstrates significant antiproliferative effects in Rb-positive tumor cells, notably in breast cancer and multiple myeloma models (Liu et al., 2021, DOI). PD 0332991 can reverse cisplatin resistance in non-small cell lung cancer by enforcing G1 arrest and promoting apoptosis. It is highly soluble in water and organic solvents with defined storage and handling parameters for research use.

    Biological Rationale

    Cyclin-dependent kinases 4 and 6 (CDK4/6) are essential for the G1 to S phase transition during cell cycle progression. Phosphorylation of the retinoblastoma (Rb) protein by CDK4/6-cyclin D complexes releases E2F transcription factors, driving cell proliferation.[1] Dysregulation of this pathway is common in cancers, including breast cancer and multiple myeloma, where Rb is functionally intact. Selective inhibition of CDK4/6 blocks Rb phosphorylation, enforcing a checkpoint and halting uncontrolled cellular proliferation.[2]

    Mechanism of Action of PD 0332991 (Palbociclib) HCl

    PD 0332991 (Palbociclib) HCl is a reversible, ATP-competitive inhibitor of CDK4 and CDK6. It exhibits potent inhibitory activity with IC50 values of 11 nM for CDK4 and 16 nM for CDK6, as determined in biochemical kinase assays (pH 7.5, 25°C, ATP at Km).[3] Inhibition of CDK4/6 activity prevents phosphorylation of Rb at serine 780/807/811, maintaining Rb in its active, hypophosphorylated form and sequestering E2F. The result is stable G1 phase arrest and suppression of genes required for S phase entry.[1] In Rb-positive cancer cell lines such as MDA-MB-453, treatment with 0.08 μmol/L PD 0332991 increases the G1 population to maximal levels within 24–48 hours.[3]

    This molecular blockade also sensitizes tumor cells to apoptosis and can reverse resistance to chemotherapeutics such as cisplatin, as evidenced in A549 and A549/CDDP non-small cell lung cancer models.[1]

    Evidence & Benchmarks

    • PD 0332991 (Palbociclib) HCl inhibits CDK4/6 with IC50 values of 11 nM and 16 nM, respectively, in vitro (APExBIO).
    • In MDA-MB-453 breast carcinoma cells, 0.08 μmol/L PD 0332991 increases G1 cell population to maximal levels within 24–48 hours (APExBIO).
    • Oral administration in Colo-205 colon carcinoma xenograft mice leads to rapid tumor regression and significant tumor cell kill at higher doses (APExBIO).
    • PD 0332991 reverses cisplatin resistance in A549/CDDP cells, increasing apoptosis to 7.03% and enforcing G1 arrest in 49.92% of cells (Liu et al., 2021, DOI).
    • Western blot analysis confirms that the Rb-E2F pathway is inhibited, preventing cell cycle re-entry in resistant lung cancer cells (Liu et al., 2021, DOI).
    • Solubility: ≥14.48 mg/mL in water, ≥2.42 mg/mL in DMSO, ≥2.79 mg/mL in ethanol (gentle warming/ultrasonication improves dissolution) (APExBIO).
    • Recommended storage: -20°C, avoiding prolonged storage of dissolved solutions (APExBIO).

    Applications, Limits & Misconceptions

    PD 0332991 (Palbociclib) HCl is widely used as a tool compound in basic and translational research on cell cycle regulation, tumor growth suppression, and mechanisms of chemoresistance. It is validated in Rb-positive breast cancer, multiple myeloma, and lung cancer models.[2] Researchers have leveraged this compound to dissect CDK4/6-dependent signaling pathways and to optimize combination regimens with DNA-damaging agents or targeted therapies.

    For a broader overview of mechanistic insights, see "PD 0332991 (Palbociclib) HCl: Mechanistic Insights into CDK4/6 Inhibition", which details transcriptional and apoptotic endpoints; this article further clarifies the compound's role in chemoresistance reversal. Additionally, "New Paradigms in CDK4/6 Inhibition" links G1 arrest with emerging mitochondrial apoptotic pathways, whereas the present article emphasizes benchmarked functional outcomes and workflow integration for laboratory use.

    Common Pitfalls or Misconceptions

    • PD 0332991 is ineffective in Rb-negative tumor cells due to absence of the molecular target (Rb protein).
    • The compound is not suitable for diagnostic or therapeutic use in humans—it is strictly for research applications (APExBIO).
    • Long-term storage of working solutions (especially in DMSO or ethanol) leads to degradation; aliquot and store at -20°C for stability.
    • CDK4/6-independent cell cycle progression (e.g., via cyclin E-CDK2) can confer resistance to PD 0332991.
    • Maximum tolerated doses and pharmacokinetics established in animal models do not directly translate to clinical conditions.

    Workflow Integration & Parameters

    PD 0332991 (Palbociclib) HCl is provided as a crystalline powder by APExBIO (SKU: A8316) and should be stored at -20°C. For in vitro experiments, dissolve in DMSO (≥2.42 mg/mL) or water (≥14.48 mg/mL), using gentle warming or ultrasonication as needed. For in vivo administration, prepare aqueous solutions freshly and avoid long-term storage. Standard working concentrations in cell-based assays range from 0.01 μmol/L to 1 μmol/L, with effects observable within 24–48 hours in most Rb-positive cell lines. For detailed application protocols and troubleshooting, see "Optimizing CDK4/6 Inhibition Workflows", which this article extends by focusing on solubility benchmarks and chemoresistance reversal.

    Conclusion & Outlook

    PD 0332991 (Palbociclib) HCl is a rigorously characterized selective CDK4/6 inhibitor and a gold standard tool in cell cycle research. Its ability to arrest Rb-positive cancer cells in G1 phase, reverse chemoresistance, and synergize with cytotoxic agents makes it indispensable for breast cancer and multiple myeloma studies.[1] Future developments may include expanded mechanistic studies on non-canonical pathways and next-generation analogs. For product details, ordering, and technical support, visit the APExBIO PD 0332991 (Palbociclib) HCl product page.